Endocrine consequences of breast cancer therapy and survivorship

References

• Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021;41(11):1183–1194. doi:10.1002/cac2.12207.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Breast Cancer 2023. Retrieved from https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
   Google Scholar
• Australian Government. Breast cancer in Australia statistics. 2023; [cited] https://www.canceraustralia.gov.au/cancer-types/breast-cancer/statistics#p.
   Google Scholar
• Taylor C, McGale P, Probert J, et al. Breast cancer mortality in 500,000 women with early invasive breast cancer diagnosed in England, 1993–2015: population based observational cohort study. BMJ. 2023;381:e074684. doi:10.1136/bmj-2022-074684.
   PubMedGoogle Scholar
• Agostinetto E, Gligorov J, Piccart M. Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nat Rev Clin Oncol. 2022;19(12):763–774. doi:10.1038/s41571-022-00687-1.
   PubMed Web of Science ®Google Scholar
• Marino JL, Saunders CM, Emery LI, et al. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause. 2014;21(3):267–274. doi:10.1097/GME.0b013e3182976f46.
   PubMed Web of Science ®Google Scholar
• Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269–275. doi:10.1007/s10549-021-06436-9.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–315. doi:10.1080/13697137.2016.1196047.
   PubMed Web of Science ®Google Scholar
• Mauri D, Gazouli I, Zarkavelis G, et al. Chemotherapy associated ovarian failure. Front Endocrinol. 2020;11:572388. doi:10.3389/fendo.2020.572388.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Boni L, Michelotti A, et al. Long-Term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients. J Natl Cancer Inst. 2022;114(3):400–408. doi:10.1093/jnci/djab213.
   PubMedGoogle Scholar
• Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-Releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-Level data. J Clin Oncol. 2018;36(19):1981–1990. doi:10.1200/JCO.2018.78.0858.
   PubMed Web of Science ®Google Scholar
• Greer AC, Lanes A, Poorvu PD, et al. The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival. Cancer. 2021;127(20):3872–3880. doi:10.1002/cncr.33601.
   PubMed Web of Science ®Google Scholar
• Daar J, Benward J, Collins L, et al. Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: an ethics committee opinion. Fertil Steril. 2018;109(6):989–992. doi:10.1016/j.fertnstert.2018.04.003.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Niman SM, Ruggeri M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645–1656. doi:10.1056/NEJMoa2212856.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2021;39(29):3293–3305. doi:10.1200/JCO.21.00535.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Ramchand SK, Milat F, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement of the endocrine society of Australia, the Australian and New Zealand bone & mineral society, the Australasian menopause society and the clinical oncology society of Australia. Clin Endocrinol. 2018;89(3):280–296. doi:10.1111/cen.13735.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23(3):382–392. doi:10.1016/S1470-2045(21)00758-0.
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Inokuchi M, Ishikawa S, et al. Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women. Springerplus. 2015;4:425. doi:10.1186/s40064-015-1223-0.
   PubMedGoogle Scholar
• Farrar MC, Jacobs TF. Tamoxifen. Petersburg: StatPearls Publishing; 2022.
   Google Scholar
• Cucciniello L, Gerratana L, Del Mastro L, et al. Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? Cancer Treat Rev. 2022;110:102445. doi:10.1016/j.ctrv.2022.102445.
   PubMed Web of Science ®Google Scholar
• Alomar SA, Găman M-A, Prabahar K, et al. The effect of tamoxifen on the lipid profile in women: a systematic review and meta-analysis of randomized controlled trials. Exp Gerontol. 2022;159:111680. doi:10.1016/j.exger.2021.111680.
   PubMed Web of Science ®Google Scholar
• Cohen I, Figer A, Tepper R, et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol. 1999;72(2):202–207. doi:10.1006/gyno.1998.5201.
   PubMed Web of Science ®Google Scholar
• Kim MK, Shin HC. Risk factors for tamoxifen-induced ovarian hyperstimulation in breast cancer patients. Clin Breast Cancer. 2020;20(5):408–412. doi:10.1016/j.clbc.2020.01.003.
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Inokuchi M, Ishikawa S, et al. Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study. BMC Cancer. 2020;20(1):67.
   PubMed Web of Science ®Google Scholar
• Jie L, Li D, Yang C, et al. Tamoxifen versus clomiphene citrate for ovulation induction in infertile women. Eur J Obstet Gynecol Reprod Biol. 2018;228:57–64. doi:10.1016/j.ejogrb.2018.06.022.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Massarotti C, Havas J, et al. Contraceptive use in premenopausal women with early breast cancer. JAMA Netw Open. 2022;5(9):e2233137. doi:10.1001/jamanetworkopen.2022.33137.
   PubMed Web of Science ®Google Scholar
• Buonomo B, Brunello A, Noli S, et al. Tamoxifen exposure during pregnancy: a systematic review and three more cases. Breast Care. 2020;15(2):148–156. doi:10.1159/000501473.
   PubMed Web of Science ®Google Scholar
• Schuurman TN, Witteveen PO, van der Wall E, et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019;175(1):17–25. doi:10.1007/s10549-019-05154-7.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141. doi:10.1016/S1470-2045(10)70257-6.
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial. J Bone Miner Res. 2006;21(8):1215–1223. doi:10.1359/jbmr.060508.
   PubMed Web of Science ®Google Scholar
• Tseng OL, Spinelli JJ, Gotay CC, et al. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2018;10(4):71–90. doi:10.1177/1759720X18759291.
   PubMed Web of Science ®Google Scholar
• Ramchand SK, Cheung YM, Yeo B, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241(3):R111–R124. doi:10.1530/JOE-19-0077.
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840–849. doi:10.1016/S1470-2045(08)70204-3.
   PubMed Web of Science ®Google Scholar
• Sverrisdóttir A, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004;22(18):3694–3699. doi:10.1200/JCO.2004.08.148.
   PubMed Web of Science ®Google Scholar
• Sestak I, Singh S, Cuzick J, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2014;15(13):1460–1468. doi:10.1016/S1470-2045(14)71035-6.
   PubMed Web of Science ®Google Scholar
• Adachi JD, Bone HG, Daizadeh NS, et al. Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM extension study. BMC Musculoskelet Disord. 2017;18(1):174. doi:10.1186/s12891-017-1520-6.
   PubMedGoogle Scholar
• Kim AS, Girgis CM, McDonald MM. Osteoclast recycling and the rebound phenomenon following denosumab discontinuation. Curr Osteoporos Rep. 2022;20(6):505–515. doi:10.1007/s11914-022-00756-5.
   PubMedGoogle Scholar
• Machairiotis N, Ntali G, Kouroutou P, et al. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Hormone Mole Biol Clin Invest. 2019;40(2):20.
   Web of Science ®Google Scholar
• Pistilli B, Paci A, Ferreira AR, et al. Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol. 2020;38(24):2762–2772. doi:10.1200/JCO.19.01758.
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Brown V, Carpenter JS, et al. The 2023 nonhormone therapy position statement of the North American Menopause Society. J North American Menopause Soc. 2023;30(6):573–590. doi:10.1097/gme.0000000000002200.
   PubMed Web of Science ®Google Scholar
• Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211–227. doi:10.1016/j.yfrne.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–1102. doi:10.1016/S0140-6736(23)00085-5.
   PubMed Web of Science ®Google Scholar
• Neal-Perry G, Cano A, Lederman S, et al. Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial. Obstet Gynecol. 2023;141(4):737–747. doi:10.1097/AOG.0000000000005114.
   PubMed Web of Science ®Google Scholar
• Vrselja A, Latifi A, Baber RJ, et al. Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2022;400(10364):1704–1711. doi:10.1016/S0140-6736(22)01977-8.
   PubMed Web of Science ®Google Scholar
• Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239–246. doi:10.1097/GME.0000000000002138.
   PubMed Web of Science ®Google Scholar
• Jacobson M, Mills K, Graves G, et al. Guideline No. 422f: menopause and breast cancer. J Obstet Gynaecol Can. 2021;43(12):1450–1456.e1. doi:10.1016/j.jogc.2021.09.011.
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135–146. doi:10.1016/S1470-2045(08)70341-3.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475–482. doi:10.1093/jnci/djn058.
   PubMedGoogle Scholar
• Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013;49(1):52–59. doi:10.1016/j.ejca.2012.07.003.
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer. 2002;95(9):1817–1826. doi:10.1002/cncr.10913.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi:10.1001/jama.288.3.321.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Bluming AZ. Hormone replacement therapy after breast cancer: it is time. Cancer J. 2022;28(3):183–190. doi:10.1097/PPO.0000000000000595.
   PubMed Web of Science ®Google Scholar
• Gérard C, Arnal J-F, Jost M, et al. Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Rev Clin Pharmacol. 2022;15(2):121–137. doi:10.1080/17512433.2022.2054413.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111. doi:10.1007/s10549-007-9523-x.
   PubMed Web of Science ®Google Scholar
• Asi N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev. 2016;5(1):121. doi:10.1186/s13643-016-0294-5.
   PubMedGoogle Scholar
• Cold S, Cold F, Jensen MB, et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347–1354. doi:10.1093/jnci/djac112.
   PubMedGoogle Scholar
• Stanczyk FZ, Mandelbaum RS, Matharu H, et al. Endometrial safety of low-dose vaginal estrogens. Menopause. 2023;30(6):650–658. doi:10.1097/GME.0000000000002177.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause. 2020;27(5):526–534. doi:10.1097/GME.0000000000001497.
   PubMed Web of Science ®Google Scholar
• Thurman A, Hull L, Stuckey B, et al. Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy. Climacteric. 2023;26(5):479–488. doi:10.1080/13697137.2023.2211763.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi:10.3109/13697137.2015.1129166.
   PubMed Web of Science ®Google Scholar
• Newman MS, Saltiel D, Smeaton J, et al. Comparative estrogen exposure from compounded transdermal estradiol creams and food and drug administration-approved transdermal estradiol gels and patches. Menopause. 2023;30(11):1098–1105. doi:10.1097/GME.0000000000002266.
   PubMed Web of Science ®Google Scholar
• Davis R, Batur P, Thacker HL. Risks and effectiveness of compounded bioidentical hormone therapy: a case series. J Womens Health. 2014;23(8):642–648. doi:10.1089/jwh.2014.4770.
   PubMed Web of Science ®Google Scholar
• Gompel A. Menopause hormone treatment after cancer. Climacteric. 2023;26(3):240–247. doi:10.1080/13697137.2023.2176216.
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29(7):767–794.
   PubMed Web of Science ®Google Scholar